Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Inflammatory Bowel Diseases

Free Subscription Articles published in Lancet Gastroenterol Hepatol Retrieve available abstracts of 137 articles: HTML format

Single Articles

May 2024
1. BETHLEHEM L, Estevinho MM, Grinspan A, Magro F, et al
   Microbiota therapeutics for inflammatory bowel disease: the way forward.
   Lancet Gastroenterol Hepatol. 2024;9:476-486.
   PubMed     Abstract available
   
   
   
2. FUMERY M, Buisson A
   Has the time come for a systematic top-down approach in Crohn's disease?
   Lancet Gastroenterol Hepatol. 2024;9:394-395.
   PubMed    
   
   
   April 2024
3. PARKES GC, Hedin CRH
   PANTS extension study: how best to use anti-TNF drugs in Crohn's disease.
   Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00088.
   PubMed    
   
   
   
4. CHANCHLANI N, Lin S, Bewshea C, Hamilton B, et al
   Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
   Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00044.
   PubMed     Abstract available
   
   
   March 2024
5. BALDERRAMO D, Quaresma AB, Olivera PA, Savio MC, et al
   Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America.
   Lancet Gastroenterol Hepatol. 2024;9:263-272.
   PubMed     Abstract available
   
   
   
6. RIVIERE P, Li Wai Suen C, Chaparro M, De Cruz P, et al
   Acute severe ulcerative colitis management: unanswered questions and latest insights.
   Lancet Gastroenterol Hepatol. 2024;9:251-262.
   PubMed     Abstract available
   
   
   February 2024
7. CHAPMAN TP, Ahmad T, Satsangi J
   Use of immunomodulators in combination with infliximab in Crohn's disease: time for a reappraisal?
   Lancet Gastroenterol Hepatol. 2024 Feb 22:S2468-1253(23)00406.
   PubMed    
   
   
   
8. NOOR NM, Lee JC, Bond S, Dowling F, et al
   A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
   Lancet Gastroenterol Hepatol. 2024 Feb 21:S2468-1253(24)00034.
   PubMed     Abstract available
   
   
   
9. CICCOCIOPPO R, Gaspar L
   Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere.
   Lancet Gastroenterol Hepatol. 2024 Feb 7:S2468-1253(24)00004.
   PubMed    
   
   
   
10. LINDSAY JO, Hind D, Swaby L, Berntsson H, et al
    Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, ra
    Lancet Gastroenterol Hepatol. 2024 Feb 7:S2468-1253(23)00460.
    PubMed     Abstract available
    
    
    January 2024
11. SEBASTIAN S, Siegmund B, Teferra F, McGovern DPB, et al
    Promoting equity in inflammatory bowel disease: a global approach to care.
    Lancet Gastroenterol Hepatol. 2024 Jan 11:S2468-1253(23)00368.
    PubMed    
    
    
    December 2023
12. FUMERY M, Buisson A
    Guselkumab in Crohn's disease: the IL-23 race continues.
    Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00356.
    PubMed    
    
    
    
13. DANESE S, Panaccione R, Feagan BG, Afzali A, et al
    Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Lancet Gastroenterol Hepatol. 2023 Dec 14:S2468-1253(23)00318.
    PubMed     Abstract available
    
    
    October 2023
14. DIBLEY L, Duffy M
    Inflammatory bowel disease health care for LGTBQIA+ patients.
    Lancet Gastroenterol Hepatol. 2023 Oct 20:S2468-1253(23)00352.
    PubMed    
    
    
    
15. PATHIYIL MM, Jena A, Venkataramana Raju AK, Omprakash TA, et al
    Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review.
    Lancet Gastroenterol Hepatol. 2023 Oct 10:S2468-1253(23)00193.
    PubMed     Abstract available
    
    
    
16. QUAN J, Markovinovic A, Hracs L, Ma C, et al
    Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Oct 6:S2468-1253(23)00310.
    PubMed    
    
    
    September 2023
17. VERMEIRE S, Danese S, Zhou W, Ilo D, et al
    Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-bl
    Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00208.
    PubMed     Abstract available
    
    
    
18. ATREYA R, Neurath MF
    Further efficacy and safety data for maintenance upadacitinib in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 Sep 5:S2468-1253(23)00271.
    PubMed    
    
    
    August 2023
19. SENIOR K
    Surgery in Crohn's disease: patients need MDT-led holistic care.
    Lancet Gastroenterol Hepatol. 2023 Aug 8:S2468-1253(23)00274.
    PubMed    
    
    
    
20. SHIN A
    Psychological therapies in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00229.
    PubMed    
    
    
    
21. RIGGOTT C, Mikocka-Walus A, Gracie DJ, Ford AC, et al
    Efficacy of psychological therapies in people with inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2023 Aug 2:S2468-1253(23)00186.
    PubMed     Abstract available
    
    
    July 2023
22. PARIGI TL, D'Amico F, Abreu MT, Dignass A, et al
    Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting.
    Lancet Gastroenterol Hepatol. 2023 Jul 6:S2468-1253(23)00154.
    PubMed     Abstract available
    
    
    May 2023
23. JULSGAARD M, Mahadevan U, Vestergaard T, Mols R, et al
    Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 May 31:S2468-1253(23)00158.
    PubMed    
    
    
    
24. JAGT JZ, van Rheenen PF, Thoma SMA, Gower J, et al
    The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership.
    Lancet Gastroenterol Hepatol. 2023 May 22:S2468-1253(23)00140.
    PubMed    
    
    
    
25. JENA A, Sharma V, Sebastian S
    Reducing disparities in training in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 May 10:S2468-1253(23)00105.
    PubMed    
    
    
    
26. BRIERLEY R
    18th Congress of the European Crohn's and Colitis Organisation.
    Lancet Gastroenterol Hepatol. 2023;8:404.
    PubMed    
    
    
    
27. LOUIS E
    Treatment de-escalation in Crohn's disease - Author's reply.
    Lancet Gastroenterol Hepatol. 2023;8:401-402.
    PubMed    
    
    
    
28. MCSHANE C, Kevans D
    Treatment de-escalation in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2023;8:401.
    PubMed    
    
    
    
29. THE LANCET GASTROENTEROLOGY HE
    The economic burden of inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023;8:391.
    PubMed    
    
    
    April 2023
30. SINGH S, Boland BS, Jess T, Moore AA, et al
    Management of inflammatory bowel diseases in older adults.
    Lancet Gastroenterol Hepatol. 2023;8:368-382.
    PubMed     Abstract available
    
    
    March 2023
31. MASSIRONI S, Vigano C, Palermo A, Pirola L, et al
    Inflammation and malnutrition in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2023 Mar 15:S2468-1253(23)00011.
    PubMed     Abstract available
    
    
    
32. BANERJEE R, Raghunathan N, Pal P
    Managing inflammatory bowel disease: what to do when the best is unaffordable?
    Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00062.
    PubMed    
    
    
    
33. BURISCH J, Zhao M, Odes S, De Cruz P, et al
    The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission.
    Lancet Gastroenterol Hepatol. 2023 Mar 2:S2468-1253(23)00003.
    PubMed     Abstract available
    
    
    February 2023
34. OTTEN AT, Bourgonje AR, Visschedijk MC
    Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD.
    Lancet Gastroenterol Hepatol. 2023;8:99-100.
    PubMed    
    
    
    
35. FEAGAN BG, Sands BE, Sandborn WJ, Germinaro M, et al
    Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
    Lancet Gastroenterol Hepatol. 2023 Feb 1:S2468-1253(22)00427.
    PubMed     Abstract available
    
    
    
36. VERMEIRE S
    Combination biologic therapy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2023 Feb 1:S2468-1253(23)00008.
    PubMed    
    
    
    January 2023
37. DREESEN E, Verstockt B
    A personalised taper-to-target strategy with adalimumab in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2023 Jan 31:S2468-1253(23)00009.
    PubMed    
    
    
    
38. VAN LINSCHOTEN RCA, Jansen FM, Pauwels RWM, Smits LJT, et al
    Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2023 Jan 31:S2468-1253(22)00434.
    PubMed     Abstract available
    
    
    
39. LOUIS E, Resche-Rigon M, Laharie D, Satsangi J, et al
    Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2023 Jan 11:S2468-1253(22)00385.
    PubMed     Abstract available
    
    
    
40. FREDERICKS E
    Treatment withdrawal in Crohn's disease: slowly becoming clearer.
    Lancet Gastroenterol Hepatol. 2023 Jan 11:S2468-1253(22)00405.
    PubMed    
    
    
    
41. KAMMERMEIER J, Lamb CA, Jones KDJ, Anderson CA, et al
    Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutri
    Lancet Gastroenterol Hepatol. 2023 Jan 9:S2468-1253(22)00337.
    PubMed     Abstract available
    
    
    
42. THORLEY J
    Severine Vermeire: advancing patient-centred research in IBD.
    Lancet Gastroenterol Hepatol. 2023;8:17.
    PubMed    
    
    
    
43. SANDBORN WJ, Panes J, Danese S, Sharafali Z, et al
    Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Lancet Gastroenterol Hepatol. 2023;8:43-55.
    PubMed     Abstract available
    
    
    December 2022
44. LIU Z, Le K, Zhou X, Alexander JL, et al
    Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a p
    Lancet Gastroenterol Hepatol. 2022 Dec 5:S2468-1253(22)00389.
    PubMed     Abstract available
    
    
    
45. ALLEGRETTI JR
    Should faecal microbiota transplantation be used earlier in the treatment framework?
    Lancet Gastroenterol Hepatol. 2022;7:1062-1063.
    PubMed    
    
    
    November 2022
46. NOOR NM, Siegel C
    Partially randomised, patient preference trials for inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022;7:981-983.
    PubMed    
    
    
    October 2022
47. ATIA O, Shavit-Brunschwig Z, Mould DR, Stein R, et al
    Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
    Lancet Gastroenterol Hepatol. 2022 Oct 25. pii: S2468-1253(22)00307.
    PubMed     Abstract available
    
    
    
48. QUAN J, Ma C, Panaccione R, Hracs L, et al
    Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022 Oct 25. pii: S2468-1253(22)00340.
    PubMed    
    
    
    September 2022
49. SELIM R, Wellens J, Brann S, Marlow L, et al
    Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy.
    Lancet Gastroenterol Hepatol. 2022 Sep 21. pii: S2468-1253(22)00302.
    PubMed    
    
    
    
50. ALEXANDER JL, Liu Z, Munoz Sandoval D, Reynolds C, et al
    COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
    Lancet Gastroenterol Hepatol. 2022 Sep 8. pii: S2468-1253(22)00274.
    PubMed     Abstract available
    
    
    
51. VERMEIRE S, Sands BE, Tilg H, Tulassay Z, et al
    ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
    Lancet Gastroenterol Hepatol. 2022 Sep 5. pii: S2468-1253(22)00233.
    PubMed     Abstract available
    
    
    
52. ATREYA R, Neurath MF
    Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2022 Sep 5. pii: S2468-1253(22)00249.
    PubMed    
    
    
    August 2022
53. TIAN H, Zhang S, Qin H, Li N, et al
    Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China.
    Lancet Gastroenterol Hepatol. 2022;7:702-703.
    PubMed    
    
    
    July 2022
54. ANANTHAKRISHNAN AN, Kaplan GG, Bernstein CN, Burke KE, et al
    Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus.
    Lancet Gastroenterol Hepatol. 2022;7:666-678.
    PubMed     Abstract available
    
    
    
55. MEIMA-VAN PRAAG EM, van Rijn KL, Wasmann KATGM, Snijder HJ, et al
    Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:617-626.
    PubMed     Abstract available
    
    
    June 2022
56. WATERMEYER G, Awuku Y, Fredericks E, Epstein D, et al
    Challenges in the management of inflammatory bowel disease in sub-Saharan Africa.
    Lancet Gastroenterol Hepatol. 2022 Jun 29. pii: S2468-1253(22)00048.
    PubMed     Abstract available
    
    
    
57. WATERMEYER G, Katsidzira L, Setshedi M, Devani S, et al
    Inflammatory bowel disease in sub-Saharan Africa: epidemiology, risk factors, and challenges in diagnosis.
    Lancet Gastroenterol Hepatol. 2022 Jun 29. pii: S2468-1253(22)00047.
    PubMed     Abstract available
    
    
    
58. ROSEIRA J, Estevinho MM, Bernardo S, Sousa P, et al
    Clinical efficacy of endoscopic balloon dilation for Crohn's disease strictures.
    Lancet Gastroenterol Hepatol. 2022;7:503.
    PubMed    
    
    
    
59. GENERE JR, Deepak P, Kochhar GS
    Reframing self-expandable metal stents for Crohn's strictures.
    Lancet Gastroenterol Hepatol. 2022;7:503-504.
    PubMed    
    
    
    
60. GELDOF J, Iqbal N, LeBlanc JF, Anandabaskaran S, et al
    Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials.
    Lancet Gastroenterol Hepatol. 2022;7:576-584.
    PubMed     Abstract available
    
    
    May 2022
61. PARIGI TL, D'Amico F, Abreu MT, Rubin DT, et al
    Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.
    Lancet Gastroenterol Hepatol. 2022;7:390-391.
    PubMed    
    
    
    
62. THE LANCET GASTROENTEROLOGY HE
    Opacity over live vaccines in infants exposed to infliximab.
    Lancet Gastroenterol Hepatol. 2022;7:379.
    PubMed    
    
    
    April 2022
63. WELLENS J, Brann S, Adams A, Marlow L, et al
    Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022 Apr 6. pii: S2468-1253(22)00120.
    PubMed    
    
    
    
64. HAIFER C, Paramsothy S, Kaakoush NO, Leong RW, et al
    Oral faecal microbiota transplantation in ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2022;7:286-287.
    PubMed    
    
    
    
65. YUAN TY, Rajesh R, Tan M
    Oral faecal microbiota transplantation in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2022;7:286.
    PubMed    
    
    
    
66. UNGARO RC, Colombel JF
    Treat to target with ustekinumab for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:276-277.
    PubMed    
    
    
    
67. DANESE S, Vermeire S, D'Haens G, Panes J, et al
    Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Lancet Gastroenterol Hepatol. 2022;7:294-306.
    PubMed     Abstract available
    
    
    
68. LORAS C, Andujar X, Gornals JB, Sanchiz V, et al
    Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:332-341.
    PubMed     Abstract available
    
    
    
69. GOREN I, Rieder F
    Endoscopic interventions for stricturing Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:279-280.
    PubMed    
    
    
    
70. SCHULBERG JD, Wright EK, Holt BA, Hamilton AL, et al
    Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2022;7:318-331.
    PubMed     Abstract available
    
    
    March 2022
71. MATSUOKA K, Watanabe M, Ohmori T, Nakajima K, et al
    AJM300 (carotegrast methyl), an oral antagonist of alpha4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Gastroenterol Hepatol. 2022 Mar 30. pii: S2468-1253(22)00022.
    PubMed     Abstract available
    
    
    
72. KOTZE PG, Heuthorst L, Lightner AL, Damiao AOMC, et al
    New insights on the surgical management of ulcerative colitis in the 21st century.
    Lancet Gastroenterol Hepatol. 2022 Mar 29. pii: S2468-1253(22)00001.
    PubMed     Abstract available
    
    
    February 2022
73. KUENZIG ME, Widdifield J, Bernatsky S, Kaplan GG, et al
    Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada.
    Lancet Gastroenterol Hepatol. 2022 Feb 22. pii: S2468-1253(22)00054.
    PubMed    
    
    
    
74. ALEXANDER JL, Kennedy NA, Ibraheim H, Anandabaskaran S, et al
    COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
    Lancet Gastroenterol Hepatol. 2022 Feb 3. pii: S2468-1253(22)00005.
    PubMed     Abstract available
    
    
    
75. PAPAMICHAEL K, Afif W, Drobne D, Dubinsky MC, et al
    Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
    Lancet Gastroenterol Hepatol. 2022;7:171-185.
    PubMed     Abstract available
    
    
    
76. OZPOLAT HT, Baran B, Akyuz F
    Septic arthritis: a presentation of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:196.
    PubMed    
    
    
    January 2022
77. GUILLO L, Abreu M, Panaccione R, Sandborn WJ, et al
    Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases.
    Lancet Gastroenterol Hepatol. 2022 Jan 17. pii: S2468-1253(21)00297.
    PubMed     Abstract available
    
    
    
78. SASSON AN
    A whole-food exclusion diet as monotherapy for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:6-7.
    PubMed    
    
    
    
79. SHEN B, Kochhar GS, Rubin DT, Kane SV, et al
    Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.
    Lancet Gastroenterol Hepatol. 2022;7:69-95.
    PubMed     Abstract available
    
    
    
80. YANAI H, Levine A, Hirsch A, Boneh RS, et al
    The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:49-59.
    PubMed     Abstract available
    
    
    December 2021
81. HAIFER C, Paramsothy S, Kaakoush NO, Saikal A, et al
    Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Dec 2. pii: S2468-1253(21)00400.
    PubMed     Abstract available
    
    
    
82. FISCHER M, Khoruts A
    Oral lyophilised microbiota for the treatment of ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 Dec 2. pii: S2468-1253(21)00433.
    PubMed    
    
    
    
83. AHMED W, Lukin DJ
    A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease.
    Lancet Gastroenterol Hepatol. 2021;6:973-975.
    PubMed    
    
    
    
84. SO D, Tuck CJ
    Plant-based diets in gastrointestinal disorders: something, nothing, or everything?
    Lancet Gastroenterol Hepatol. 2021;6:992.
    PubMed    
    
    
    
85. THOMAS H
    UEG Week Virtual 2021.
    Lancet Gastroenterol Hepatol. 2021;6:990.
    PubMed    
    
    
    
86. SINGH S, Murad MH, Fumery M, Sedano R, et al
    Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Lancet Gastroenterol Hepatol. 2021;6:1002-1014.
    PubMed     Abstract available
    
    
    November 2021
87. LASA JS, Olivera PA, Danese S, Peyrin-Biroulet L, et al
    Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00377.
    PubMed     Abstract available
    
    
    
88. MA C, Choi MY
    Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00432.
    PubMed    
    
    
    
89. TAKENAKA K, Fujii T, Kawamoto A, Suzuki K, et al
    Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00372.
    PubMed     Abstract available
    
    
    
90. PEYRIN-BIROULET L, Hart A, Bossuyt P, Long M, et al
    Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00298.
    PubMed     Abstract available
    
    
    
91. DANESE S, Colombel JF, Lukas M, Gisbert JP, et al
    Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00294.
    PubMed     Abstract available
    
    
    
92. VERMEIRE S, Lakatos PL, Ritter T, Hanauer S, et al
    Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00295.
    PubMed     Abstract available
    
    
    
93. RUBIN DT, Dotan I, DuVall A, Bouhnik Y, et al
    Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00338.
    PubMed     Abstract available
    
    
    
94. AGRAWAL M, Verstockt B
    Etrolizumab for ulcerative colitis: beyond what meets the eye.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00369.
    PubMed    
    
    
    
95. MOURAD FH, Hashash JG
    Inflammatory bowel disease in Lebanon: a plea for help.
    Lancet Gastroenterol Hepatol. 2021 Nov 11. pii: S2468-1253(21)00390.
    PubMed    
    
    
    
96. ASWANI-OMPRAKASH T, Sharma V, Bishu S, Balasubramaniam M, et al
    Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance.
    Lancet Gastroenterol Hepatol. 2021;6:884-885.
    PubMed    
    
    
    October 2021
97. SELIM R, Wellens J, Marlow L, Satsangi JJ, et al
    SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy.
    Lancet Gastroenterol Hepatol. 2021 Oct 13. pii: S2468-1253(21)00347.
    PubMed    
    
    
    
98. ALEXANDER JL, Selinger CP, Powell N
    Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Oct 12. pii: S2468-1253(21)00374.
    PubMed    
    
    
    
99. SHEN B, Kochhar GS, Kariv R, Liu X, et al
    Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.
    Lancet Gastroenterol Hepatol. 2021;6:826-849.
    PubMed     Abstract available
    
    
    
100. HANAUER S, Liedert B, Balser S, Brockstedt E, et al
     Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
     Lancet Gastroenterol Hepatol. 2021;6:816-825.
     PubMed     Abstract available
     
     
     September 2021
101. SHEN B, Bortlik M, Bruining DH, Coelho-Prabhu N, et al
     Endoscopic evaluation after surgery in inflammatory bowel disease - Authors' reply.
     Lancet Gastroenterol Hepatol. 2021;6:691-692.
     PubMed    
     
     
     
102. SYAL G, Fleshner PR, Melmed GY
     Endoscopic evaluation after surgery in inflammatory bowel disease.
     Lancet Gastroenterol Hepatol. 2021;6:690-691.
     PubMed    
     
     
     
103. KOBAYASHI T
     Stringent criteria for withdrawal of biologics in ulcerative colitis - Authors' reply.
     Lancet Gastroenterol Hepatol. 2021;6:688.
     PubMed    
     
     
     
104. TAN M, Ng V, Lim CT, Leow WQ, et al
     Stringent criteria for withdrawal of biologics in ulcerative colitis.
     Lancet Gastroenterol Hepatol. 2021;6:687-688.
     PubMed    
     
     
     August 2021
105. FIORINO G, Allocca M, Danese S
     Adalimumab biosimilar in inflammatory bowel disease.
     Lancet Gastroenterol Hepatol. 2021 Aug 10. pii: S2468-1253(21)00266.
     PubMed    
     
     
     
106. GEYL S, Guillo L, Laurent V, D'Amico F, et al
     Transmural healing as a therapeutic goal in Crohn's disease: a systematic review.
     Lancet Gastroenterol Hepatol. 2021;6:659-667.
     PubMed     Abstract available
     
     
     July 2021
107. SASSON AN, Ingram RJM, Zhang Z, Taylor LM, et al
     The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease.
     Lancet Gastroenterol Hepatol. 2021 Jul 13. pii: S2468-1253(21)00097.
     PubMed     Abstract available
     
     
     
108. GARRIDO HMG, Grobusch MP, D'Haens GRAM, Goorhuis A, et al
     SARS-CoV-2 vaccination for patients with inflammatory bowel disease.
     Lancet Gastroenterol Hepatol. 2021;6:523.
     PubMed    
     
     
     
109. ALEXANDER JL, Kennedy NA, Lees CW, Ahmad T, et al
     SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply.
     Lancet Gastroenterol Hepatol. 2021;6:523-524.
     PubMed    
     
     
     
110. DIN S, Gaya DR, Arnott IDR
     COVID-19: Colorectal cancer endoscopic surveillance in IBD.
     Lancet Gastroenterol Hepatol. 2021;6:526-527.
     PubMed    
     
     
     June 2021
111. CROFT NM, Faubion WA Jr, Kugathasan S, Kierkus J, et al
     Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
     Lancet Gastroenterol Hepatol. 2021 Jun 18. pii: S2468-1253(21)00142.
     PubMed     Abstract available
     
     
     May 2021
112. ALEXANDER JL, Powell N
     SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?
     Lancet Gastroenterol Hepatol. 2021 May 25. pii: S2468-1253(21)00184.
     PubMed    
     
     
     
113. DANESE S, Parigi TL, Peyrin-Biroulet L, Ghosh S, et al
     Defining difficult-to-treat inflammatory bowel disease: why and how.
     Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00141.
     PubMed    
     
     
     
114. ALSOUD D, Verstockt B, Fiocchi C, Vermeire S, et al
     Breaking the therapeutic ceiling in drug development in ulcerative colitis.
     Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00065.
     PubMed     Abstract available
     
     
     
115. SEGAL JP, Kumar A, Raine T, Lamb CA, et al
     The impact of SARS-CoV-2 variants on IBD management.
     Lancet Gastroenterol Hepatol. 2021;6:343-344.
     PubMed    
     
     
     April 2021
116. UNGAR B
     Infliximab discontinuation in patients with ulcerative colitis.
     Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00103.
     PubMed    
     
     
     
117. KOBAYASHI T, Motoya S, Nakamura S, Yamamoto T, et al
     Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
     Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00062.
     PubMed     Abstract available
     
     
     
118. SHEN B, Kochhar GS, Navaneethan U, Cross RK, et al
     Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group.
     Lancet Gastroenterol Hepatol. 2021 Apr 16. pii: S2468-1253(20)30394.
     PubMed     Abstract available
     
     
     March 2021
119. BARBERIO B, Zamani M, Black CJ, Savarino EV, et al
     Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.
     Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00014.
     PubMed     Abstract available
     
     
     
120. KEEFER L
     What can we do to tackle anxiety and depression in patients with inflammatory bowel disease?
     Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00066.
     PubMed    
     
     
     
121. SEGAL JP, Kayal M, Kochhar G, Dubinsky MC, et al
     The ileoanal pouch: the next frontier in inflammatory bowel disease.
     Lancet Gastroenterol Hepatol. 2021;6:164-165.
     PubMed    
     
     
     
122. JENA A, Jha DK, Sharma V
     Distinguishing intestinal tuberculosis from Crohn's disease.
     Lancet Gastroenterol Hepatol. 2021;6:159.
     PubMed    
     
     
     
123. BANERJEE R, Pal P
     Distinguishing intestinal tuberculosis from Crohn's disease - Authors' reply.
     Lancet Gastroenterol Hepatol. 2021;6:159-160.
     PubMed    
     
     
     February 2021
124. SEBASTIAN S, Walker GJ, Kennedy NA, Conley TE, et al
     Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.
     Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00016.
     PubMed     Abstract available
     
     
     
125. SHEN B
     Acute severe ulcerative colitis: confronting an intensified stressor during the COVID-19 pandemic.
     Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00009.
     PubMed    
     
     
     
126. VERMA AM, Patel A, Subramanian S, Smith PJ, et al
     From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
     Lancet Gastroenterol Hepatol. 2021;6:88-89.
     PubMed    
     
     
     January 2021
127. ALEXANDER JL, Moran GW, Gaya DR, Raine T, et al
     SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.
     Lancet Gastroenterol Hepatol. 2021 Jan 25. pii: S2468-1253(21)00024.
     PubMed     Abstract available
     
     
     December 2020
128. NG SC, Mak JWY, Pal P, Banerjee R, et al
     Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia.
     Lancet Gastroenterol Hepatol. 2020;5:1089-1100.
     PubMed     Abstract available
     
     
     
129. BANERJEE R, Pal P, Mak JWY, Ng SC, et al
     Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia.
     Lancet Gastroenterol Hepatol. 2020;5:1076-1088.
     PubMed     Abstract available
     
     
     
130. STRID H
     Prevalence of IBS-type symptoms in IBD.
     Lancet Gastroenterol Hepatol. 2020;5:1029-1031.
     PubMed    
     
     
     November 2020
131. AZIZ I, Simren M
     The overlap between irritable bowel syndrome and organic gastrointestinal diseases.
     Lancet Gastroenterol Hepatol. 2020 Nov 12. pii: S2468-1253(20)30212.
     PubMed     Abstract available
     
     
     October 2020
132. MA C, Panaccione R
     Harnessing localised delivery of gut-selective therapy for ulcerative colitis.
     Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30292.
     PubMed    
     
     
     
133. ATREYA R, Peyrin-Biroulet L, Klymenko A, Augustyn M, et al
     Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
     Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30301.
     PubMed     Abstract available
     
     
     
134. BRENNER EJ, Ungaro RC, Colombel JF, Kappelman MD, et al
     IBD in the COVID-19 era: the value of international collaboration.
     Lancet Gastroenterol Hepatol. 2020;5:887-888.
     PubMed    
     
     
     
135. STEVENS TW, Haasnoot ML, D'Haens GR, Buskens CJ, et al
     Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
     Lancet Gastroenterol Hepatol. 2020;5:900-907.
     PubMed     Abstract available
     
     
     
136. FAIRBRASS KM, Costantino SJ, Gracie DJ, Ford AC, et al
     Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.
     Lancet Gastroenterol Hepatol. 2020 Oct 1. pii: S2468-1253(20)30300.
     PubMed     Abstract available
     
     
     May 2020
137. LOUGHMAN A, Staudacher HM
     Treating the individual with diet: is gut microbiome testing the answer?
     Lancet Gastroenterol Hepatol. 2020;5:437.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.